| |
URS+
|
URS-
|
P-value
|
|---|
|
Mean±SD/ (N,%)
|
Mean±SD/ (N,%)
|
|---|
| |
3,079 (53.9)
|
2,634 (46.1)
| |
|
Gender
|
|
Male (N, %)
|
1,346 (43.72%)
|
1,126 (42.75%)
|
0.462
|
|
Female (N, %)
|
1,733 (56.28%)
|
1,508 (57.25%)
| |
|
Age (Mean±SD)
|
67.79 (±10.68)
|
67.63 (±11.15)
|
0.599
|
|
Age (N,%)
|
|
<65 years
|
1,092 (35.47%)
|
952 (36.14%)
|
0.491
|
|
65-74 years
|
1,150 (37.35%)
|
944 (35.84%)
| |
|
>74 years
|
837 (27.18%)
|
738 (28.02%)
| |
|
CCI score (N,%)
|
|
0
|
272 (8.83%)
|
341 (12.95%)
|
<0.001*
|
|
1
|
217 (7.05%)
|
245 (9.30%)
| |
| ≧2 |
2,590 (84.12%)
|
2,048 (77.75%)
| |
|
Comorbidity
|
|
Hypertension
|
|
No
|
1,443 (46.87%)
|
1,300 (49.35%)
|
0.061
|
|
Yes
|
1,636 (53.13%)
|
1,334 (50.65%)
| |
|
Hyperlipidemia
|
|
No
|
2,371 (77.01%)
|
2,138 (81.17%)
|
<0.001*
|
|
Yes
|
708 (22.99%)
|
496 (18.83%)
| |
|
Diabetes
|
|
No
|
2,345 (76.16%)
|
2,054 (77.98%)
|
0.103
|
|
Yes
|
734 (23.84%)
|
580 (22.02%)
| |
|
ESRD
|
|
No
|
2,490 (80.87%)
|
2,072 (78.66%)
|
0.038*
|
|
Yes
|
589 (19.13%)
|
562 (21.34%)
| |
- CCI Charlson Comorbidity Index, ESRD End-stage renal disease
- *p<0.05
